Land Rover has updated its Defender 4x4 with a new trim, a new bodykit, some new paint options… and cut a whopping 93bhp out ...

Generally speaking, most manufacturers aim to spruce up the appearance of a volume seller every three years or so - otherwise ...

The Boston-based drugmaker has been on a mission to build out the next generation of drug products beyond its cystic fibrosis ...

In today's Pharmaceutical Executive Daily, Vertex Pharmaceuticals announces a $10 billion acquisition of Crinetics ...

Major indexes declined Tuesday, pulled lower by chip stocks, after beginning the week with gains. The Dow Jones Industrial ...

Casgevy is now approved in the U.S. for children with sickle cell as young as 2, becoming the first gene-editing therapy for ...

On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing ...

When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...

With expected close this quarter, the stock should converge toward the deal price as deal certainty rises and spreads tighten ...

H.C. Wainwright said Crinetics’ lead product Palsonify adds a meaningful commercial product and establishes endocrinology as Vertex’s fifth major business pillar.

CRNX surges on Vertex’s $10B deal, FISV rises on STAR sale talks, RIVN drops on offering, MU slips on glut fears—read more.

The roller-coaster ride for AI stocks is snapping lower again Tuesday and weighing on Wall Street. The S&P 500 fell 0.6% even ...